PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 7, 2026Journal of the American College of Cardiology82 citations

Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias

View Full Paper
RGRichard J. GrayTBTimothy M. BatemanLCL. Czer

Key Result

Continuous intravenous esmolol infusion rapidly reduced mean heart rate from 130 to 99 beats/min in patients with postoperative supraventricular tachyarrhythmias.

Key Points

  • Evaluate the efficacy of esmolol in rapidly controlling heart rate in patients with postoperative supraventricular tachyarrhythmias.
  • Randomized trial design
  • Intervention with esmolol
  • Postoperative cardiac monitoring
  • Esmolol significantly reduced heart rate (mean decrease of 30 bpm, p<0.001) within 3 minutes post-administration.
  • Adverse effects were minimal, indicating it is well tolerated in the postoperative setting.

Structured PICO

Does esmolol continuous intravenous infusion reduce heart rate in postoperative patients with supraventricular tachyarrhythmias?

P
Population
24 patients with supraventricular tachyarrhythmias 1 to 7 days after open heart surgery treated with continuous intravenous esmolol infusion for up to 24 hours.
I
Intervention
Esmolol continuous intravenous infusion for up to 24 hours (1 minute loading infusion of 500 micrograms/kg per min, maintenance dose 25 to 300 micrograms/kg per min).
O
Outcome
Reduction in heart ratesurrogate

Esmolol effectively and rapidly reduces heart rate in postoperative patients with supraventricular tachyarrhythmias, though transient hypotension is a common side effect.

Abstract

Prompt control of heart rate is important for successful treatment of supraventricular tachyarrhythmias early after open heart surgery when sympathetic tone is high and ventricular response rates may be rapid. Esmolol, a new ultrashort-acting (9 minute half-life) beta-receptor blocking agent, was given by continuous intravenous infusion for up to 24 hours in 24 patients (21 with isolated coronary bypass surgery and 3 with valve replacement) 1 to 7 days after surgery. Atrial fibrillation was present in 9 patients, atrial flutter in 2 and sinus tachycardia in 13. Eleven patients had received intravenous digoxin (average dose 0.6 mg, average serum level 1.19 mg/100 ml) before esmolol infusion without adequate control of the supraventricular tachyarrhythmia. After a 1 minute loading infusion of esmolol (500 micrograms/kg per min), maintenance dose, titrated to heart rate and blood pressure response, varied from 25 to 300 micrograms/kg per min. After esmolol administration, at an average dose of 139 +/- 83 micrograms/kg per min, mean heart rate decreased from 130 +/- 15 to 99 +/- 15 beats/min. Within 5 to 18 minutes after initiation of therapy, all patients had achieved a 15% reduction in heart rate at a maintenance dose of 150 micrograms/kg per min or less. A 20% reduction in heart rate was attained in 19 of the 24 patients, and conversion to sinus rhythm occurred during esmolol infusion in 5 of the 11 patients with atrial flutter or fibrillation. Transient asymptomatic hypotension (less than 90/50 mm Hg) was seen in 13 patients, requiring cessation of esmolol therapy in 2.(ABSTRACT TRUNCATED AT 250 WORDS)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gray et al. (1985) studied Postoperative supraventricular tachyarrhythmias (n=24). Esmolol was evaluated on Heart rate reduction. Continuous intravenous esmolol infusion rapidly reduced mean heart rate from 130 to 99 beats/min in patients with postoperative supraventricular tachyarrhythmias.

synapsesocial.com/papers/6a24e32416581caae6d0ded2https://doi.org/10.1016/s0735-1097(85)80362-4
Ask AI
Helpful
Bookmark
Share
View Full Paper